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Abstract
Background: To investigate whether the incorporation of 18FDG-PET into the automatic treatment planning
process may be able to decrease the dose to active bone marrow (BM) for locally advanced anal cancer
patients undergoing concurrent chemo-radiation (CHT-RT).
Methods: Ten patients with locally advanced anal cancer were selected. Bone marrow within the pelvis was
outlined as the whole outer contour of pelvic bones or employing 18FDG-PET to identify active BM within
osseous structures. Four treatment planning solutions were employed with different automatic optimization
approaches toward bone marrow. Plan A used iliac crests for optimization as per RTOG 05–29 trial; plan B
accounted for all pelvic BM as outlined by the outer surface of external osseous structures; plan C took into
account both active and inactive BM as defined using 18FDG-PET; plan D accounted only for the active BM
subregions outlined with 18FDG-PET. Dose received by active bone marrow within the pelvic (ACTPBM) and
in different subregions such as lumbar-sacral (ACTLSBM), iliac (ACTIBM) and lower pelvis (ACTLPBM) bone
marrow was analyzed.
Results: A significant difference was found for ACTPBM in terms of Dmean (p = 0.014) V20 (p = 0.015), V25 (p = 0.030), V30
(p = 0.020), V35 (p = 0.010) between Plan A and other plans. With respect to specific subsites, a significant difference was
found for ACTLSBM in terms of V30 (p = 0.020)), V35 (p = 0.010), V40 (p = 0.050) between Plan A and other
solutions. No significant difference was found with respect to the investigated parameters between Plan B,C
and D. No significant dosimetric differences were found for ACTLSPBM and ACTIBM and inactive BM subregions
within the pelvis between any plan solution.
Conclusions: Accounting for pelvic BM as a whole compared to iliac crests is able to decrease the dose to active bone
marrow during the planning process of anal cancer patients treated with intensity-modulated radiotherapy. The same
degree of reduction may be achieved optimizing on bone marrow either defined using the outer bone contour or
through 18FDG-PET imaging. The subset of patients with a benefit in terms of dose reduction to active BM through the
inclusion of 18FDG-PET in the planning process needs further investigation.
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Background
At present, concurrent chemo-radiation (CHT-RT) is a
standard therapeutic option in patients with squamous
cell carcinoma of the anal canal [1, 2]. Given the high
repopulation rate of this type of tumor, treatment
compliance is crucial to avoid unintended interruptions
potentially extending overall treatment time [3]. In
adjunct, maintaining a proper package of chemotherapy
(CHT) administration in terms of number of cycles and
dose is important to achieve adequate tumor control.
Hence, decreasing the toxicity profile associated to
CHT-RT is crucial. If non-conformal techniques are
used, as in the RTOG 98–11 trial, crude rates of major
acute toxicities can be as high as 48% for skin and 35%
for the gastrointestinal district [4]. Intensity-modulated
radiotherapy (IMRT) provides robust conformality and
modulation, abrupt dose fall-off and reliable consistency
and may reduce the dose to organs at risk such as bladder,
bowel, perineal skin, genitalia and bone marrow, poten-
tially lowering toxicity [5]. However, even with this
approach, acute toxicity is not negligible, as seen in the
RTOG 05–29 trial [6]. In this subset of patients, another
key endpoint for treatment tolerance is hematologic
toxicity (HemT) that can affect compliance to therapy,
increasing the likelihood to develop bleeding, infections or
fatigue [7]. The most important trigger for HemT is CHT
that induces myelosuppression [8]. Nevertheless, since
bone marrow (BM) is highly radiosensitive and, in the
average adult population, is comprised for half of its ex-
tension within pelvic bones and lumbar vertebrae, the ra-
diation dose received by this compartment may be critical
[9, 10]. Several retrospective studies correlated different
dose parameters of pelvic osseous structures to HT in dif-
ferent oncological scenarios [11–13]. Thus, selective spar-
ing of pelvic bones is thought to be a suitable option to
decrease HemT during concomitant CHT-RT in patients
affected with pelvic malignancies including anal cancer
[10]. The correct identification of BM within bony struc-
tures is the starting point to avoid it during RT. Several
approaches have been used. Contouring the whole bone is
the method with the highest chance to be inclusive with
respect to BM [11]. Delineating the marrow cavity identi-
fied as the trabecular bone with lower density on
computed tomography is another option [14]. The
identification of hematopoietically active bone marrow
using either magnetic resonance (MR), single-photon-
emission positron tomography (SPECT), 18F–fluoro-
deoxyglucose-labeled positron-emission tomography
(18FDG-PET) or 3′-deoxy-3′-18F-fluorothymidine-la-
beled positron-emission tomography (18FLT-PET),
gives the potential opportunity to selectively avoid the
portion of BM responsible for blood cells generation
[15–18]. Aim of the present planning comparison
study is to test the hypothesis that the use of 18FDG-
PET to identify pelvic active BM to be employed
during automatic optimization process might enhance
the chance to reduce the dose to the same structures
compared to a planning process based on the whole-
bone delineation of pelvic bones. This preliminary
study aims at finding the most appropriate planning
approach to be integrated within a prospective phase II trial
in preparation at our Institute to decrease the hematologic
toxicity profile in anal cancer patients undergoing CHT-
RT, employing dose-painted image-guided IMRT.
Methods
Ten patients affected with locally advanced squamous
cell carcinoma of the anal canal and/or margin were re-
trieved from our Institutional databased and employed
for the present study. In our center, 18FDG-PET-CT
exam is prescribed to all anal cancer patients prior to
treatment in order to complete the diagnostic and sta-
ging work-up. These examinations were employed for
our analysis. Hence, it was not necessary to submit any
patient to an extra diagnostic procedure for the present
study. Written informed consent was obtained from all
patients, for 18FDG-PET-CT examination, radiotherapy
treatment and clinical data utilization. The Review Board
of the Department of Oncology at the University of
Turin approved the present study. Overall patient and
tumor characteristics are shown in Table 2. Tumors
were staged according to the 7th edition of the TNM
classification (2010).
Delineation of target volumes and organs at risk
Patients had a virtual simulation procedure in supine
position with both an indexed shaped knee rest and
ankle support (CIVCO Medical Solutions, Kalona, IO,
USA), without custom immobilization. A CT scan was
performed with 3 mm slice thickness axial images
acquired from the top of L1 vertebral body to the mid-
femural bones. The gross tumor volume (GTV) com-
prised all primary and nodal macroscopic disease and
was defined based on diagnostic MR and PET-CT im-
ages. Primary and nodal GTVs were expanded isotropic-
ally with 20 mm and 10 mm respectively to generate the
corresponding clinical target volumes (CTVs) and then
modified to exclude osseous and muscular tissues. The
elective CTV encompassed the whole mesorectum and
draining lymphatic regions, namely inguinal, external
and internal iliac, obturator and perirectal nodes. For
locally advanced cases (cT4 and/or N2/N3), presacral
nodes were also included within the CTV. Lymphatic
areas were contoured as a 10 mm isotropic expansion
surrounding regional vessels and then modified to
exclude bones and muscles. Thereafter a 10 mm isotropic
margin was added for the corresponding planning target
volume (PTV) to account for organ motion and set up
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errors. Bladder, small and large bowel, external genitalia,
femoral heads were defined as organs at risk (OARs).
Radiotherapy dose prescription
Dose prescriptions for target volumes were derived from
Kachnic et al. and adjusted according to clinical stage at
presentation [6]. Patients diagnosed with cT3-T4/N0-N3
disease were prescribed 54 Gy/30 fractions (1.8–2 Gy
daily) to the anal gross tumor PTV, while gross nodal
PTVs were prescribed 50.4 Gy/30 fr (1.68 Gy daily) if sized
≤3 cm or 54 Gy/30 fr (1.8 Gy daily) if >3 cm; elective
nodal PTV was prescribed 45 Gy/30 fractions (1.5 Gy
daily) [6]. This is a frequently used fractionation to deliver
IMRT treatments in this setting and it is a standard
approach in our Institution [1–3, 5]. This is the reason
why it was chosen for the present study.
Chemotherapy
All patients received concurrent CHT, consisting of 5-
fluorouracil (5-FU) (1000 mg/m2/day) given as continu-
ous infusion along 96 h (days 1–5 and 29–33) associated
with mitomycin C (MMC) (10 mg/m2, capped at max-
imum 20 mg single dose) given as bolus (days 1 and 29).
A total of 2 concurrent cycles were administered.
Bone marrow delineation
The external contour of pelvic bone marrow (PBM) was
outlined on the planning CT using bone windows as first
described by Mell et al. [11]. The PBM was delineated as
a whole and then divided into 3 subsites: a) the iliac BM
(IBM), extending from the iliac crests to the upper
border of femoral head; b) lower pelvis BM (LPBM),
accounting for bilateral pube, ischia, acetabula and prox-
imal femura, from the upper limit of the femoral heads
to the lower limit of the ischial tuberosities and c) lum-
bosacral BM (LSBM), extending from the superior
border of L5 somatic body [11].
Active bone marrow delineation on FDG-PET
All images derived from planning CT were exported on
the Velocity platform (Varian Medical Systems, Palo
Alto, CA) together with treatment volumes, OARs and
dose references. Given that FDG-PET-CT images were
acquired separately, we performed a rigid co-registration
between planning CT and PET-CT images. Patients were
set up in treatment position during the acquisition of
FDG-PET-CT. The 18FDG-PET standardized uptake
values (SUVs) were calculated for PBM volumes, after
correcting for body weight. To standardize SUVs among
all patients, we normalized BM and liver SUVs. We
defined as active bone marrow BM the volume having
higher SUV values than the SUVmean for each patient,
rather than the whole cohort, as proposed by Rose et
al. [19, 20]. The areas identified with the method
described above were outlined within PBM as a whole
and named ACTPBM and within each of the 3 subre-
gions identified on planning CT (LSBM, IBM, LPBM)
and named ACTLSBM, ACTIBM, ACTLPBM, respect-
ively. Inactive BM (1-ACTPBM) was identified as the
difference between BM volumes as defined on plan-
ning CT and active BM. The same procedure was
done for all 3 subregions to identify inactive BM
within all of them. The 3 volumes were hence called
1-ACTLSBM, 1-ACTIBM, 1-ACTLPBM.
Planning process
All treatment plans were generated using the Pinnacle3
ver. 9.1 platform (Philips, Eindhoven, The Netherlands),
including the Auto-planning (AP) module. The AP en-
gine is a progressive region of interest (ROI)-based
optimization tool that creates all the required contours
iteratively in order to optimize the dose distribution and
takes PTV/OARs overlaps into account during the
optimization process. Moreover, AP is able to adjust the
priority of clinical goals based on the probability to be
achieved. Besides clinical objectives and priorities, AP
has a compromise setting to allow for sparing of serial
organs such as the spinal cord over targets, and ad-
vanced settings to allow for setting global parameters
such as priorities between targets and OARs, dose fall-
off, maximum dose and cold spot management. Therefore
the main input data required by AP to drive optimization
are: target optimization goal, i.e. prescription dose to the
PTVs, engine type (biological or non biological), OARs
optimization goals (max dose, max DVH or mean dose),
priority (high, medium or low) and compromise (yes or no
depending on the strength of the constraint). The standard
OARs considered in the optimization process were: bladder
(Dmax,Dmean,V35,V40,V50 as relative volumes), femural heads
(Dmax,Dmean,V30,V40, as relative volumes), external genitalia
(Dmax,Dmean,V20,V30,V40 as relative volumes), large and
small bowel (Dmax,Dmean,V30,V45, as absolute volumes), iliac
crests (V30,V40,V50 as relative volumes) and pelvic BM
defined either as whole bone contour or using 18FDG-PET
(lowest dose as possible) (Table 1). Four type of plans were
created accounting for the various BM delineation ap-
proaches. Each of the four trials was optimized considering
BM as additional OAR (Fig. 1):
Plan A. IBM (reference plan; accounting only for iliac
crest as per RTOG 05–29 trial)
Plan B. IBM, LSBM, PBM and LPBM (accounting for
all the pelvic BM as outlined by the outer surface of
external osseous structures)
Plan C. ACTLSBM, ACTIBM, ACTLPBM, 1-ACTLSBM,
1-ACTIBM, 1-ACTLPBM (accounting for both the
active BM subregions as defined by 18FDG-PET but
also for the remaining parts of bony structures, to
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address a possible uncertainty in the SUV based
delineation process. Higher priority was assigned to
active BM regions)
Plan D. ACTLSBM, ACTIBM, ACTLPBM (accounting only
for the active BM subregions as defined by
18FDG-PET)
See Fig. 1 for visual description of the 4 planning solu-
tions with respect to the considered BM structures. A
similar PTV coverage and avoidance of “standard” OARs
were required among the plans. A comparison of the
dose received by active pelvic BM (ACTPBM, ACTLSBM,
ACTIBM, ACTLPBM) with the 4 different approaches was
done in terms of DVH parameters such as Dmax,
Dmean and Vx where x was varied from 5 to 45 Gy with
5 Gy steps of progressive increase.
Statistical analysis
All the results are reported as the sample mean and
standard deviation (SD) of all 98 dosimetric parameters
subdivided in four groups. Multiple comparisons were
performed using univariate analysis of variance
(ANOVA). ANOVA provides a statistical test of whether
or not the means of several groups are all equal, and
therefore generalizes the Student t-test to more than
two groups. The difference between multiple subsets of
data is considered statistically significant if ANOVA
gives a significance level P (P value) less than 0.05,
otherwise was reported as not significant (NS). In cases
where the ANOVA resulted as statistically significant we
evaluated the probability that the means of two popula-
tions were equal using Fisher-Hayter pairwise compari-
sons. This post-test approach is used in statistics when
Table 1 Dose constraints to target volume and organs at risk
employed during optimization
Parameter Goal
PTV D95% ≥95%
Dmax ≤107%
Bladder V30 <50%
V40 <35%
V50 <5%
Large bowel V30 <200cm
3
V35 <150cm
3
V40 <20cm
3
Dmax <50Gy
Small bowel V30 <200cm
3
V35 <150cm
3
V40 <20cm
3
Dmax <50Gy
External genitalia V20 <50%
V30 <35%
V40 <5%
Femural heads V30 <50%
V40 <35%
V50 <5%
Iliac crests V30 <50%
V40 <35%
V50 <5%
Legend: PTV planning target volume, V20,30,35,40,50 volumes receiving
20,30,35,40,50 Gy, cc cubic centimeters
Fig. 1 Visual representation of the 4 planning approaches. Bone marrow is represented in red. Optimization was addressed to iliac crest in Plan A
(a), the whole pelvic bones defined as external osseous contour in Plan B (b), active (red) and inactive (yellow) bone marrow as defined with
18FDG-PET (c) with a higher priority for active and a lower for inactive, active bone marrow only as defined with 18FDG-PET (d)
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one needs to address pairs comparison in multiple
groups after running ANOVA. The STATA software
package (Stata Statistical Software: Release 13.1. Stata
Corporation, College Station, TX, 2013) was used for all
statistical analysis.
Results
Detailed characteristics of the 10 selected patients are
shown in Table 2. Mean age at diagnosis was 65. Sex
was equally distributed. Most of the patients had a
locally advanced disease presentation (Stage IIIB: 80%),
with monolateral involvement of pelvic lymphnodes
(external and internal iliac nodes), which was deemed
more challenging to be tested in the planning process.
The mean absolute overlap volume between ACTPBM and
elective nodal PTV (the more sized volume containing
also macroscopic nodal and tumor volumes) was 95.4 cm3
(SD: ± 37.5 cm3). Mean ACTPBM absolute volume was
799.9 cm3 (SD: ± 100.8 cm3). The mean relative overlap
volume was 12.2% (SD: ± 5.2%). No differences were
observed among the 4 planning solutions in terms of
target coverage and dose to OARs (bladder, bowel,
genitalia and femoral heads. With respect to the dose
received by BM delineated as the whole osseous contour
of pelvic bones, no significant differences were found in
terms of Dmax and Dmean to PBM, LPBM and IBM and in
terms of V30,V40 and V45 for IBM between Plan A, B,C
and D. The only significant difference (p = 0.038) was
found in terms of Dmean to LSBM between Plan A
(Dmean = 30.88; SD = 3.68) and Plan B (Dmean = 26.44;
SD = 3.85) or Plan C (Dmean = 26.52; SD = 3.97) (see
Table 3). With respect to the dose received by active BM
within the whole pelvic bones, as outlined using 18FDG-
PET, a significant difference was found in terms of Dmean
to ACTPBM (p = 0.014) between Plan A (Dmean = 29.33;
SD = 2.38) vs Plan C (Dmean = 25.76; SD: 2.74) and Plan D
(Dmean = 26.02; SD = 2.69) (Table 4). Several other dosi-
metric parameters were significantly different for ACTPBM
such as V20 (p = 0.015) between Plan A (Mean = 74.26%;
SD = 7.13) vs Plan C (Mean = 63.50%; SD = 8.59) and
Plan D (Mean = 64.24%; SD = 8.43), V25 (p = 0.030) be-
tween Plan A (Mean = 63.49%; SD = 7.48) vs Plan C
(Mean = 51.49%; SD = 7.52) and Plan D (Mean = 52.18%;
SD = 7.97),V30 (p = 0.020) between Plan A (Mean = 52.63%;
SD = 7.17) vs Plan C (Mean = 40.27%; SD = 7.12) and
Plan D (Mean = 41.31%; SD = 7.71), V35 (p = 0.010) be-
tween Plan A (Mean = 41.72%; SD = 6.78) vs Plan B
(Mean = 33.35%; SD = 6.13), Plan C (Mean = 30.06%;
SD = 6.43) and Plan D (Mean = 31.14%; SD = 6.73), V40
(p = 0.020) between Plan A (Mean = 28.82%; SD = 5.67)
vs Plan B (Mean = 21.54%; SD = 5.10), Plan C
(Mean = 19.94%; SD = 7.27) and Plan D (Mean = 20.67%;
SD = 5.24) (Table 4). Focusing on different subsites, a sig-
nificant difference was found for ACTLSBM in terms of
V30 (p = 0.020) between Plan A (Mean = 66.53%;
SD = 11.19) vs Plan B (Mean = 52.06%; SD = 13.20),
Plan C (Mean = 50.07%; SD = 13.19) and Plan D
(Mean = 51.46%; SD = 12.97), V35 (p = 0.010) be-
tween Plan A (Mean = 56.95%; SD = 12.73) vs Plan B
(Mean = 42.15%; SD = 12.79), Plan C (Mean = 40.19%;
SD = 11.90) and Plan D (Mean = 41.42%; SD = 12.30),
V40 (p = 0.050) between Plan A (Mean = 41.04%;
SD = 14.37) vs Plan C (Mean = 28.17%; SD = 9.40).
No significant difference was found in terms of any
dosimetric parameter for ACTLSPBM and ACTIBM
between any plan solution (Table 5). Again, no statis-
tically significant difference was found for every dose
metric analyzed between 1-ACTPBM, 1-ACTLSBM, 1-
ACTIBM, 1-ACTLPBM among all planning approaches
(Table 3).
Discussion
HemT may be a clinically meaningful issue in anal can-
cer patients submitted to concomitant CHT-RT, poten-
tially affecting patient’s compliance to treatment, disease
control and survival [7]. For example, in the RTOG 98–
11 trial, where RT was delivered with anterior-posterior
Table 2 Patient and treatment characteristics
Variable N° (%)
Age
Mean 65
Rage 50–78
Sex
Female 5 (50%)
Male 5 (50%)
T stage
T2 5 (50%)
T3 5 (50%)
N stage
N0–1 2 (20%)
N2 6 (60%)
N3 2 (20%)
Global stage
II 2 (20%)
IIIB 8 (80%)
PTV dose-tumor (Gy)
54 Gy 10 (100%)
PTV dose-positive nodes (Gy)
54 Gy 2 (20%)
50.4 Gy 5 (50%)
PTV dose-elective volumes (Gy)
45 Gy 10 (10%)
Legend: T tumor, N nodal, N° number, PTV planned target volume
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parallel opposed fields with the eventual addition of
paired laterals, grade 3 and 4 HemT rates were 61% in
patients treated with 5-FU/MMC-based CHT-RT and
42% in those submitted to cisplatin and 5-FU [4, 7].
Even in most recent series, with RT delivered employing
IMRT approaches (either static or volumetric), major
acute HemT rates ranges between 20% to 50% [5, 7].
Chemotherapy is the most important trigger for HemT,
since it causes direct myelosuppression [7, 8]. Radiation
dose to the hematopoietically active reservoir plays a
role and the combination of RT and CHT, typical in anal
cancer patients, strongly enhances the toxicity profile
toward BM [11, 12]. This observation is particularly crucial
in the setting of pelvic malignancies, since pelvic bones
harvest a high relative proportion of active BM [7, 8].
Hayman et al. investigated the relative distribution of active
BM through the body, using 18FLT-PET, in 13 patients
affected with different types of cancer, observing that
25.3% was at the pelvis, 16.6% at lumbar spine and 9.2% at
the sacrum [21]. In adjunct, in a recent study, McGuire et
al. demonstrated that regions located in the central part of
the pelvis (upper sacrum, inner halves of iliac crests and
the 5th lumbar vertebral body), have the highest uptake of
18FLT [18]. Similar results were obtained by Franco et al.
using 18FDG with the evidence of up to 67% of active bone
marrow comprised within the sacrum relative to the whole
sacral bone volume [17]. Hence, from a radiation oncology
perspective, a potential strategy to decrease the HemT pro-
file in this subset of patients, is to selectively spare osseous
structures within the pelvis during the radiotherapy
planning and delivery process [7]. That means that areas
containing hematopoietically active bone marrow needs to
be properly outlined on the planning CT and taken into
account during the planning process with appropriate
dose-constraints to drive isodose line distribution. An ideal
BM-sparing approach must come without compromising
coverage of target volumes and avoidance of other organs
at risk, such as bladder, bowel, genitalia and femoral heads.
The ideal strategy to selectively spare pelvic BM has yet to
be established. With the present planning comparison
study, we tried to answer this question, in order to find out
the most suitable planning approach to be used within a
prospective phase II trial starting at our Institution to
decrease the acute HemT profile in anal cancer patients
submitted to CHT-RT and treated with dose-painted
image-guided IMRT. For the optimization process, we
needed consistency and reproducibility of the planning
workflow. We tried to avoid excessive inter-operator vari-
ability within planning solutions. Hence, we decided to
employ the Pinnacle3 Auto-planning platform as suitable
Table 3 Comparison of doses to pelvic bone marrow and its subsistes (defined with outer bone contours) and to inactive bone
marrow and its subsites (defined with 18FDG-PET) among the 4 plans
Plan A Plan B Plan C Plan D p ≤ 0.05 ANOVA Fisher-Hayter test
Structure Parameter Mean SD(+/−) Mean SD(+/−) Mean SD(+/−) Mean SD(+/−)
PBM Dmax 53.50 2.30 53.57 2.20 53.55 2.13 53.73 2.09 NS
Dmean 25.72 2.44 23.30 2.38 23.25 2.81 23.58 2.74 NS
LSBM Dmax 48.56 2.17 48.83 1.79 49.21 1.88 49.27 1.95 NS
Dmean 30.88 3.68 26.44 3.85 26.52 3.97 26.97 3.80 0.038 A vs B and C
IBM Dmax 48.64 3.04 48.89 3.17 49.35 2.99 49.16 3.21 NS
Dmean 22.16 1.59 21.57 1.48 20.48 2.31 20.84 2.38 NS
V30 24.58 4.74 24.65 3.76 21.14 6.60 22.06 7.36 NS
V40 7.13 3.03 6.34 2.75 6.65 2.42 7.18 2.70 NS
V45 1.15 1.90 1.09 2.15 1.49 1.53 1.45 1.81 NS
LPBM Dmax 53.60 2.45 53.76 2.33 53.89 2.33 54.01 2.27 NS
Dmean 25.99 4.12 23.76 4.36 24.46 4.62 24.60 4.48 NS
1- ACTPBM Dmax 53.38 2.25 53.38 2.12 53.36 2.05 53.55 2.09 NS
Dmean 22.70 3.58 20.21 3.40 21.18 3.92 21.56 3.79 NS
1-ACTLSBM Dmax 48.32 2.17 48.60 1.85 48.94 1.90 48.95 2.00 NS
Dmean 28.95 4.43 24.00 4.88 25.12 3.93 25.83 3.74 NS
1-ACTIBM Dmax 48.60 3.06 48.70 3.32 49.24 3.07 49.06 3.17 NS
Dmean 19.98 3.65 18.96 3.59 19.05 3.71 19.43 3.77 NS
1-ACTLPBM Dmax 53.28 2.20 53.27 2.04 53.36 2.05 53.38 2.01 NS
Dmean 21.85 4.16 19.60 3.88 20.77 4.82 21.06 4.60 NS
Legend: Dmax maximal dose, Dmean mean dose, SD standard deviation, V30,40,45 relative volume receiving 30,40,45 Gy, PBM pelvic bone marrow, LSBM lumbar-sacral
bone marrow, IBM iliac bone marrow, LPBM lower pelvis bone marrow,ACT active, A, B, C plan A, B, C, NS non significant
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option to answer this need. With this tool we were able to
consistently decrease the amount of variability due to
different operators and to provide constant robustness to
the optimization process. We compared 4 different
approaches. The basic approach (Plan A) was taken from
the RTOG 05–29 trial and optimization on BM was
limited to the iliac crests (IBM), as outlined on planning
CT using the external surface of bones as reference. This
strategy did not take into account for the part of BM com-
prised within sacrum and ischiatic bones. Plan B included
in the planning algorithm the whole pelvis (all 3 subsites:
IBM, LSBM, LPBM) delineated using the outer surface on
CT. This approach, based on Mell et al. contouring proto-
col, took into account the whole BM comprised within
pelvic bones, but not that within lumbar vertebrae [11].
Conversely, Plan C and D employed functional imaging
for active BM identification within pelvic bones, as previ-
ously described [17, 19, 20]. In Plan C, the highest priority
was given to active BM defined with 18FDG-PET, but
inactive BM was also taken into account in the planning
process with a lower priority score. This approach was
chosen considering the observation by Rose et al., who
showed that both active and inactive BM as defined using
18FDG-PET may be associated to neutrophilic cell nadir
[20]. In plan D, we accounted only for active BM within
the pelvis as a structure to be spared. In general, no
significant differences were found in terms of target cover-
age and organs at risk (other than BM) avoidance among
all plan solutions, highlighting the fact that neither of
these approaches negatively affected those treatment
objectives. The inclusion in the optimization process of
pelvic subsites other than iliac crests (IBM) such as LSBM
and LPBM, lead to a significant decrease in the mean dose
to LSBM (not to IBM, LPBM or PBM as a whole). For
IBM this is due to the fact that this region was included as
OAR in all 4 planning strategies. For LPBM, a possible
explanation could be the low dose to the structure
obtained with all 4 methods and for PBM, which is the
summation of all 3 subregions, the insufficient contribu-
tion of LSBM mean dose reduction to the whole pelvis
dose (Table 3). This finding means that, compared to the
RTOG 05–29 planning strategy of addressing iliac crest
only in the optimization process, a more comprehensive
approach may further spare BM comprised in the lumbar-
Table 4 Comparison of doses to active whole pelvic and lumbar-sacral bone marrow (defined with 18FDG-PET) among the 4 plans
Plan A Plan B Plan C Plan D p ≤ 0.05 ANOVA Fisher-Hayter test
Structure Parameter Mean SD(+/−) Mean SD(+/−) Mean SD(+/−) Mean SD(+/−)
ACTPBM Dmax 52.67 2.72 52.93 2.82 53.03 2.79 53.18 2.63 NS
Dmean 29.33 2.38 26.99 2.38 25.76 2.74 26.02 2.69 0.014 A vs C and D
V5 94.59 4.23 92.85 5.05 92.57 5.32 92.71 5.11 NS
V10 87.84 6.04 85.10 7.10 84.05 7.73 84.35 7.53 NS
V15 82.82 7.06 78.54 7.52 75.17 9.14 75.82 8.44 NS
V20 74.26 7.13 68.58 6.94 63.50 8.59 64.24 8.43 0.015 A vs C and D
V25 63.49 7.48 56.35 6.90 51.49 7.52 52.18 7.97 0.030 A vs C and D
V30 52.63 7.17 44.87 6.71 40.27 7.12 41.31 7.71 0.020 A vs C and D
V35 41.72 6.78 33.35 6.13 30.06 6.43 31.14 6.73 0.010 A vs B,C and D
V40 28.82 5.67 21.54 5.10 19.94 7.27 20.67 5.24 0.020 A vs B,C and D
V45 9.16 3.51 7.64 2.75 7.20 2.83 6.91 2.21 NS
ACTLSBM Dmax 48.46 2.01 48.66 1.51 49.08 1.70 49.13 1.54 NS
Dmean 37.86 18.56 27.87 4.38 27.35 4.65 27.65 4.40 NS
V5 89.89 8.72 87.71 9.16 87.24 9.48 87.43 9.30 NS
V10 83.87 8.66 79.88 9.49 79.18 10.58 79.32 10.03 NS
V15 79.94 9.09 74.87 9.99 74.19 11.68 74.46 10.64 NS
V20 77.23 9.44 68.80 11.31 67.97 13.53 68.45 11.75 NS
V25 73.13 10.15 60.88 12.60 59.46 14.15 60.71 12.54 NS
V30 66.53 11.19 52.06 13.20 50.07 13.19 51.46 12.97 0.020 A vs B,C and D
V35 56.95 12.73 42.15 12.79 40.19 11.90 41.42 12.30 0.010 A vs B,C and D
V40 41.04 14.37 29.81 10.52 28.17 9.40 29.29 9.72 0.050 A vs C
V45 16.11 12.75 10.53 5.13 9.48 3.92 9.23 3.74 NS
Legend: Dmax maximal dose, Dmean mean dose, SD standard deviation, V5,10,15,20,25,30,35,40,45 relative volume receiving 5,10,15,20,25,30,35,40,45 Gy, PBM pelvic bone
marrow, LSBM lumbar-sacral bone marrow, ACT active, A, B, C, D plan A,B,C, D, NS non significant
Franco et al. BMC Cancer  (2017) 17:710 Page 7 of 11
sacral region (Plan A - Dmean = 30.88 vs Plan B -
Dmean = 26.44 and Plan C -Dmean = 26.52; p = 0.038). This
may be important since LSBM may contain a higher pro-
portion of hematopoietically active BM and the RT dose
received by this subsite has been demonstrated to be
highly involved in the occurrence of acute HemT [14, 17].
Using the external surface of LSBM (Plan B) or 18FDG-
PET-defined ACTLSBM seems not to play a role in the
chance to reduce LSBM mean dose. This can be partially
due to the relative overlap volume between PTV and
ACTPBM, which was, on average, as high as 12.2% in our
set of patients. Focusing on the dose received by active
bone marrow outlined with 18FDG-PET within pelvic
bones employing the 4 different planning strategies,
several interesting findings can be pointed out. The mean
dose received by the active BM within the whole pelvis
(ACTPBM) could be significantly reduced by including
other subsites than iliac crest in the optimization process
(Plan A - Dmean = 29.33 vs Plan C - Dmean = 25.76 and
Plan D - Dmean = 26.02; p = 0.014). This reduction in the
mean dose is mainly driven by a reduction in the ACTPBM
volumes receiving doses ranging from 20 Gy to 40 Gy
(significant difference in terms of V20,V25,V30,V35 and V40
between Plan A and others, as seen in Table 3). The
subsite the mostly contributes to the reduction of
ACTPBM dose is ACTLSBM whose volume receiving doses
ranging from 30 Gy to 40 Gy was significantly different
between Plan A and other solutions (V30,V35,V40; see
Table 3). The chance to reduce ACTLSBM and conse-
quently ACTPBM doses addressing all pelvic subsites
during the planning process seems to be similar with all
modalities employed (Plan B,C and D). Our study may be
of interest because it is the first one to report on the dose
received by 18FDG-PET-defined BM within the pelvis,
after optimization on both BM defined on functional
imaging (Plan C and D) and using the external bone
contour (Plan B). Our dosimetric data are, in general,
lower than those reported to have clinical meaningfulness
in patients affected with pelvic malignancies. For example
in cervical cancer patients, Mell et al. showed that patients
having PBM- V10 ≥ 90% and PBM V20 ≥ 75% were most
likely to develop ≥ G2 leukopenia and to have chemother-
apy held [11]. Accordingly, Rose et al. found that PBM-
V10 ≥ 95% and PBM V20 ≥ 76% were associated to a
Table 5 Comparison of doses to iliac and lower pelvic bone marrow (defined with 18FDG-PET) among the 4 plans
Plan A Plan B Plan C Plan D p ≤ 0.05 ANOVA
Structure Parameter Mean SD(+/−) Mean SD(+/−) Mean SD(+/−) Mean SD(+/−)
ACTIBM Dmax 48.19 3.11 48.34 3.22 48.77 3.21 48.68 3.37 NS
Dmean 24.44 6.63 24.22 2.56 22.28 3.65 22.63 3.62 NS
V5 96.74 4.70 96.20 6.16 95.82 6.27 95.52 6.66 NS
V10 90.99 8.49 89.74 9.65 87.22 12.22 87.89 11.38 NS
V15 84.31 10.64 81.75 12.04 74.75 17.13 76.28 16.98 NS
V20 66.15 9.73 65.45 11.85 55.52 15.35 57.14 15.83 NS
V25 45.84 8.97 46.28 9.29 37.87 11.85 37.80 12.04 NS
V30 29.15 8.09 30.23 5.82 23.82 8.82 24.89 9.31 NS
V35 16.43 6.62 16.82 4.14 13.33 5.82 14.75 5.98 NS
V40 7.48 4.37 6.61 3.19 5.95 3.24 6.67 3.13 NS
V45 0.94 1.57 0.93 1.86 1.02 1.24 1.05 1.46 NS
ACTLPBM Dmax 52.66 2.71 52.93 2.82 53.00 2.86 53.14 2.70 NS
Dmean 33.09 4.61 30.63 4.70 29.34 4.80 29.54 4.63 NS
V5 98.30 3.37 96.93 5.11 97.15 5.66 98.01 4.14 NS
V10 90.09 9.01 88.32 9.85 89.50 9.28 88.95 10.05 NS
V15 86.12 10.76 82.13 12.69 80.73 14.49 81.07 12.61 NS
V20 82.07 12.89 76.19 13.85 71.53 15.41 72.34 14.82 NS
V25 75.68 14.62 67.33 14.57 61.89 15.33 63.45 15.46 NS
V30 66.78 15.38 57.91 14.86 51.34 13.93 52.29 14.28 NS
V35 55.63 15.81 46.22 13.29 40.63 12.42 41.33 12.55 NS
V40 38.94 12.30 32.28 10.88 29.06 10.86 29.37 10.56 NS
V45 16.98 7.53 14.15 6.52 13.54 7.12 12.89 8.85 NS
Legend: Dmax maximal dose, Dmean mean dose, SD standard deviation, V5,10,15,20,25,30,35,40,45 relative volume receiving 5,10,15,20,25,30,35,40,45 Gy, IBM iliac bone
marrow, LPBM lower pelvis bone marrow, ACT active, A, B, C plan A, B, C, NS non significant
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higher chance to develop ≥ G3 leukopenia in a similar
cohort [22]. We were able to be consistently below these
thresholds with all the 4 strategies, but those employing
functional imaging (Plan C and D) seemed to be the most
promising, particularly with respect to ACTPBM-V20,
which was 63.5% and 64.2% with these 2 solutions (see
Table 4). In anal cancer patients, Bazan et al. showed that
patients with PBM mean dose ≥30 Gy had a 14-fold
increase in the odds of developing ≥ G3 HemT [23]. More-
over, according to Lyman-Kutcher-Burman modeling,
Franco et al. outlined that LSBM mean dose should be
kept <32 Gy to minimize >G3 HemT rates in a similar
population [24]. In the present study, ACTPBM mean
dose was below 27 Gy with plan B,C and D approaches
with (non significantly) lower values for the strategies
employing 18FDG-PET. In adjunct ACTLSBM mean
dose was consistently below 28 Gy for the 3 strategies
(B,C,D), with similar reduction entity. In a previous
study, Franco et al. demonstrated, in anal cancer
patients, that those having a LSBM-V40 ≥ 41% were
more likely to develop ≥G3 HemT [12]. Plan B,C and D
were able to obtain LSBM-V40 values consistently
below 30%, with no significant difference among the 3
planning strategies. Our data seem to show that, at
least for a patient cohort of anal cancer patient as in
Table 1, the optimization on BM as the whole osseous
contour is able to spare BM similarly to that defined on
18FDG-PET. The paradigm in this setting, is that func-
tional imaging (18FDG-PET in this case) is able to cor-
rectly detect active BM within bony structures,
identifying subvolumes smaller the those outlined by
the whole bone contour and that may be optimized
more easily without compromising target coverage and
avoidance of other organs at risk [10, 16, 18]. Our data
seems to suggest that this assumption is not trivial and
that optimization on whole bone contour may be as
efficient. This may be due to the fact that ACTPBM dose
reduction was driven in our study by ACTLSBM dose
decrease. It has been shown that the relative proportion
of active BM within LSBM is as high as 67% and hence
in this case the outer contour of LSBM may be a valid
surrogate of ACTLSBM [17]. Moreover LSBM and
ACTLSBM are centrally located and usually in close
proximity to primary tumor and macroscopic node
treatment volumes and hence sparing one (mainly from
high-dose) means sparing the other. Nevertheless, the
other consideration is that BM distribution within the
bones can be very different. Campbell et al. investigated
BM distribution according to 18F–FLT-PET in a cohort
of 51 lung cancer patients. Women had a higher pro-
portion of functional BM in the pelvis, proximal femurs
and skull, while men in the sternum and ribs, clavicles
and scapulae. Elderly patients (> 75 years) had a higher
relative proportion of active BM in the ribs, clavicles
and scapulae [25]. Because of the slenderness of the
sample size, we did not perform any subset analysis,
but the relative proportion of active BM may be differ-
ent among the 3 different subsites (LSBM, IBM and
LPBM) and within the same subsite, depending on
patient’s characteristics (sex and age for example) and
intrinsic variability. The optimization of the whole bone
contour is efficient but does not take into account indi-
vidual variability, while the one based on functional
imaging may be able to do it. Another point is that BM
distribution within the pelvis may undergo substantial
changes during the course of RT-CHT, because of the
clonal expansion of red marrow due to the trigger of
antiblastic treatments. Functional imaging may be able
to record and track this modifications [26]. However,
the most appropriate quantitative imaging strategy to
identify active BM has yet to be established. Several
different methods have been investigated such as SPECT,
18FDG-PET, 18FLT-PET and quantitative MR. All the
aforementioned tools have different characteristics with
respect to sensitivity and specificity to detect active BM,
magnitude and reliability of the quantitative information
provided and availability among the radiation oncology
facilities [27]. In this sense 18FDG-PET is a reasonable
choice in terms of cost-effectiveness. This is important
because sparing pelvic BM as defined with 18FDG-PET
has clinical meaningfulness. This has been demonstrated
in a prospective frame in the setting of cervical cancer,
with the INTERTECC-2 trial, where patients treated with
concurrent RT-CHT developed a lower rate of ≥ G3
neutropenia, if treated with a 18FDG-PET-driven pelvic
BM-sparing IMRT approach [28].
Conclusions
Our study demonstrates that accounting for all subsites
during the optimization process decreases the dose to
active bone marrow as detected using functional imaging
with 18F–FDG-PET in anal cancer patients, compared to
the optimization process based only on iliac crests out-
lined on planning CT as in the RTOG 05–29 protocol. A
similar degree of reduction can be obtained through
optimization based on external bone contour or based
on 18F–FDG-PET – based functional imaging, which not
necessarily is beneficial for all patients. However, specific
subset of patients with certain active BM relative distri-
bution and spatial correlation between target, BM and
other organs at risk may benefit from this approach. The
characteristics of this subset of patients have yet to be
determined in future studies.
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